Cybin Reports Dosing of First Two Patients in P-I/IIa Clinical Trial of CYB003 for the Treatment of Major Depressive Disorder
Shots:
- The first two patients have been dosed in the P-I/IIa trial evaluating the PK, safety & response/remission of CYB003 @3 & 6wks. in patients (aged 21-55yrs.) receiving a PBO/active & an active/active dose. The trial will also evaluate the rapid onset of antidepressant effect on the day of dosing by using MADRS along with the incremental benefit of the 2nd dose when administered @3wks.
- The preclinical data of CYB003 showed a similar in vitro & in vivo pharmacology profile to psilocin, 50% reduction in variability & dose, shorter time of onset (50%) & a double brain penetration
- The preclinical data has also shown less variability of CYB003 in plasma levels, faster onset of action & shorter duration of effect
Ref: Businesswire | Image: Cybin
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
